ONCOCROSS
ONCOCROSS
Industry:
Biotechnology Pharmaceutical
Founded:
2015-06-22
Address:
Mapo, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.oncocross.com
Total Employee:
1+
Status:
Active
Contact:
02-867-9967
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Global Site Tag Mobile Non Scaleable Content Euro Google Analytics 4
Similar Organizations
Takeda Oncology
Takeda Oncology is a leading biopharmaceutical company.
Current Employees Featured
Founder
Official Site Inspections
http://www.oncocross.com Semrush global rank: 7.45 M Semrush visits lastest month: 492
- Host name: ec2-52-79-216-114.ap-northeast-2.compute.amazonaws.com
- IP address: 52.79.216.114
- Location: Incheon South Korea
- Latitude: 37.4562
- Longitude: 126.7288
- Timezone: Asia/Seoul
- Postal: 21539
More informations about "Oncocross"
ONCOCROSS : we make drugs works
Oncocross is innovating the drug development process through its unique AI approach. We develop treatments for cancers, rare diseases, and intractable diseases through our transcriptome data based AI platform. About us. โฆSee details»
Oncocross - Crunchbase Company Profile & Funding
Oncocross may be growing as it has initiated a technical evaluation process, which could indicate an expansion of its operations or development of new products. The company has also โฆSee details»
Oncocross 2025 Company Profile: Stock Performance โฆ
Oncocross Co Ltd is innovating the drug development process through its AI approach for developing treatments for cancers, rare diseases, and intractable โฆSee details»
Oncocross - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Mar 4, 2021: Corporate Round โฆSee details»
Yi Rang Kim - Chairman - Council for AI Drug Discovery โฆ
ONCOCROSS Chief Executive Officer · Council for AI Drug Discovery & Development (CAIDD) · KAIST · Seoul · 500+ connections on LinkedIn. View โฆSee details»
Cyclica and Oncocross Announce Partnership to โฆ
Jul 5, 2022 Cyclica Inc., a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, and Oncocross Co., Ltd., a biotech revolutionizing the drug development process through its unique AI โฆSee details»
Oncocross Expands Collaboration with JW Pharmaceutical on โฆ
SEOUL, South Korea, May 27, 2024--Oncocross, a Seoul-based AI drug discovery and development biotech, announced on May 22nd that it has signed a joint research agreement โฆSee details»
Oncocross Co., Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Oncocross announced that it had demonstrated the objective safety and pharmacokinetic pro OC514 through the safety evaluation and the analysis of pharmacokinetic parameters โฆSee details»
๊ณผํ์๋ฌธ์์ํ - ์จ์ฝํฌ๋ก์ค : we make drugs works - Oncocross
๊ณผํ์๋ฌธ์์ํ - ์จ์ฝํฌ๋ก์ค๋ ์ธ๊ณต์ง๋ฅ์ ๊ธฐ๋ฐ์ผ๋ก ์์ฝ๊ฐ๋ฐ๋ถ์ผ์ ํ์ ์ ๋ง๋ค์ด ๊ฐ๋ฉฐ, ์ธ๊ณต์ง๋ฅ ์น๋ฃ์ ๋ฐ๊ตด์ ํตํด ์๋ฃ ์๋น์ค์ ์์ธ๋๋ ์ฌ๋์ด ์๋๋ก ๋ ๋์ ์ธ์์ ๋ง๋ค์ด ๊ฐ๋๋ค.See details»
AI startups team up with drugmakers for drug repurposing
Apr 2, 2021 Oncocross has raised a total of 25.5 billion won ($22.6 million) through Series A and B funding in 2019 and 2020, respectively. Under the latest MOU with Oncocross, Daewoong โฆSee details»
Oncocross - Crunchbase
Organization. Oncocross . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. โฆSee details»
์ ์ฃผ ๋ฐํ ๊ณต๊ณ (์ 3์๋ฐฐ์ ์ ๋ณ๊ฒฝ) - ์จ์ฝํฌ๋ก์ค - Oncocross
์ ์ฃผ ๋ฐํ ๊ณต๊ณ (์ 3์๋ฐฐ์ ์ ๋ณ๊ฒฝ) 2022.05.25; ์ด์ ๊ธ ์ 8ํ ์ ๊ธฐ์ฃผ์ฃผ์ดํ ์์ง๊ณต๊ณ 2023.03.14 ๋ค์๊ธSee details»
ONCOCROSS CO LTD innovation strategy - GoodIP
ONCOCROSS CO LTD has a total of 32 patent applications. It increased the IP activity by 500.0%. Its first patent ever was published in 2015. It filed its patents most often in Republic of โฆSee details»
Oncocross Management - Simply Wall St
Mar 28, 2025 Learn about Oncocross Co., Ltd. (A382150) stock's management team. Comprehensive performance, salary and tenure analysis for the CEO, board and leadership โฆSee details»
Oncocross Co., Ltd. Business Operations, SWOT, PESTLE ... - Quaintel
Jan 11, 2025 Figure 1: Oncocross Co., Ltd. - Head Office - Country Figure 2: Oncocross Co., Ltd. - Key Subsidiaries Figure 3: Oncocross Co., Ltd. - SWOT Analysis Figure 4: Competing โฆSee details»
OncoCross, an artificial intelligence (AI)-based new drug โฆ
Dec 18, 2024 Oncocross shares surged to 97.95% of the offering price at one point in early trading, approaching the "tumble." Earlier, OncoCross decided to set the public offering price โฆSee details»
๋ณด๋์๋ฃ - ์จ์ฝํฌ๋ก์ค : we make drugs works - oncocross.com
Feb 24, 2023 CEO ๊น์ด๋ Address ์์ธ ์กํ๊ตฌ ๋ฒ์๋ก11๊ธธ 7 (๋ฌธ์ ๋) 905ํธ (๋ฌธ์ ๋, ๋ฌธ์ ํ๋์ง์์ฐ์ ์ผํฐ 1-2) Tel 02-717-9967 Fax 02-867-9968See details»
OnCoCross Income Statement - Investing.com
Explore the detailed OnCoCross Co Ltd income statement, offering a comprehensive view of the companyโs financial performance. Review essential metrics such as revenue, gross profit, โฆSee details»
์จ์ฝํฌ๋ก์ค(A382150) | Snapshot | ๊ธฐ์ ์ ๋ณด | Company Guide
5 days ago PER(Price Earning Ratio) ์ ์ผ์ ๋ณดํต์ฃผ ์์ ์ฃผ๊ฐ / ์ต๊ทผ ๊ฒฐ์ฐ EPS(์ฃผ๋น์์ด์ต) * EPS = ๋น๊ธฐ์์ด์ต / ์์ ํ๊ท ๋ฐํ์ฃผ์์See details»
Press - ONCOCROSS : we make drugs works
Feb 24, 2023 Press - We make drugs work. We value nothing more important than life. Through our AI technology, we strive to develop drugs for every single patient suffering from intractable โฆSee details»